Comparison of early hemodynamic performance of 3 aortic valve bioprostheses

Murat Ugur, Rakesh M. Suri, Richard C. Daly, Joseph A. Dearani, Soon J. Park, Lyle D. Joyce, Harold M. Burkhart, Kevin L. Greason, Hartzell V Schaff

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective The study objective was to determine whether the new-generation Trifecta (St Jude Medical Inc, St Paul, Minn) bovine aortic valve bioprosthesis, which is designed for supra-annular positioning, produces early postoperative hemodynamic results comparable to or better than those of the Mitroflow (Sorin Group, Milan, Italy) or Perimount Magna (Edwards Lifesciences Corp, Irvine, Calif) bovine aortic valve bioprostheses.

Methods We retrospectively reviewed the medical records of patients who underwent aortic valve replacement with a Trifecta, Mitroflow, or Perimount Magna bovine pericardial prosthesis at Mayo Clinic between June 2007 and December 2012 and analyzed early postoperative hemodynamic performance by Doppler echocardiography.

Results A total of 1436 patients underwent aortic valve replacement (Trifecta in 196, Mitroflow in 1135, Perimount Magna in 105). Preoperative characteristics and early clinical outcomes were similar among the 3 valve groups. The average mean gradients were lower and valve areas were greater with the Trifecta valves. For the Trifecta, Mitroflow, and Perimount Magna valves, the average mean gradient was 11.4 mm Hg, 16.9 mm Hg, and 14.1 mm Hg, respectively; the effective orifice area was 2.22 cm2, 1.85 cm2, and 2.09 cm2, respectively; and the indexed effective orifice area was 1.14 cm2/m2, 0.96 cm2/m2, and 1.07 cm2/m2, respectively (all P <.001). Similar statistical significance was found when data were stratified by valve size. Severe prosthesis-patient mismatch (indexed effective orifice area <0.60 cm2/m2) was detected in 1.3% of patients (n = 2/150) with the Trifecta, 5.8% of patients (n = 44/758) with the Mitroflow, and 3.2% of patients (n = 3/95) with the Perimount Magna (P =.048).

Conclusions Early hemodynamic postoperative performance of the Trifecta bioprosthesis is favorable. Additional follow-up should determine whether these small hemodynamic differences will persist and influence later clinical outcomes.

Original languageEnglish (US)
Pages (from-to)1940-1946
Number of pages7
JournalJournal of Thoracic and Cardiovascular Surgery
Volume148
Issue number5
DOIs
StatePublished - Nov 1 2014

Fingerprint

Bioprosthesis
Aortic Valve
Hemodynamics
Prostheses and Implants
Doppler Echocardiography
Italy
Medical Records

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Comparison of early hemodynamic performance of 3 aortic valve bioprostheses. / Ugur, Murat; Suri, Rakesh M.; Daly, Richard C.; Dearani, Joseph A.; Park, Soon J.; Joyce, Lyle D.; Burkhart, Harold M.; Greason, Kevin L.; Schaff, Hartzell V.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 148, No. 5, 01.11.2014, p. 1940-1946.

Research output: Contribution to journalArticle

Ugur, M, Suri, RM, Daly, RC, Dearani, JA, Park, SJ, Joyce, LD, Burkhart, HM, Greason, KL & Schaff, HV 2014, 'Comparison of early hemodynamic performance of 3 aortic valve bioprostheses', Journal of Thoracic and Cardiovascular Surgery, vol. 148, no. 5, pp. 1940-1946. https://doi.org/10.1016/j.jtcvs.2013.12.051
Ugur, Murat ; Suri, Rakesh M. ; Daly, Richard C. ; Dearani, Joseph A. ; Park, Soon J. ; Joyce, Lyle D. ; Burkhart, Harold M. ; Greason, Kevin L. ; Schaff, Hartzell V. / Comparison of early hemodynamic performance of 3 aortic valve bioprostheses. In: Journal of Thoracic and Cardiovascular Surgery. 2014 ; Vol. 148, No. 5. pp. 1940-1946.
@article{fc9a76bba94748e08995058f67544c2b,
title = "Comparison of early hemodynamic performance of 3 aortic valve bioprostheses",
abstract = "Objective The study objective was to determine whether the new-generation Trifecta (St Jude Medical Inc, St Paul, Minn) bovine aortic valve bioprosthesis, which is designed for supra-annular positioning, produces early postoperative hemodynamic results comparable to or better than those of the Mitroflow (Sorin Group, Milan, Italy) or Perimount Magna (Edwards Lifesciences Corp, Irvine, Calif) bovine aortic valve bioprostheses.Methods We retrospectively reviewed the medical records of patients who underwent aortic valve replacement with a Trifecta, Mitroflow, or Perimount Magna bovine pericardial prosthesis at Mayo Clinic between June 2007 and December 2012 and analyzed early postoperative hemodynamic performance by Doppler echocardiography.Results A total of 1436 patients underwent aortic valve replacement (Trifecta in 196, Mitroflow in 1135, Perimount Magna in 105). Preoperative characteristics and early clinical outcomes were similar among the 3 valve groups. The average mean gradients were lower and valve areas were greater with the Trifecta valves. For the Trifecta, Mitroflow, and Perimount Magna valves, the average mean gradient was 11.4 mm Hg, 16.9 mm Hg, and 14.1 mm Hg, respectively; the effective orifice area was 2.22 cm2, 1.85 cm2, and 2.09 cm2, respectively; and the indexed effective orifice area was 1.14 cm2/m2, 0.96 cm2/m2, and 1.07 cm2/m2, respectively (all P <.001). Similar statistical significance was found when data were stratified by valve size. Severe prosthesis-patient mismatch (indexed effective orifice area <0.60 cm2/m2) was detected in 1.3{\%} of patients (n = 2/150) with the Trifecta, 5.8{\%} of patients (n = 44/758) with the Mitroflow, and 3.2{\%} of patients (n = 3/95) with the Perimount Magna (P =.048).Conclusions Early hemodynamic postoperative performance of the Trifecta bioprosthesis is favorable. Additional follow-up should determine whether these small hemodynamic differences will persist and influence later clinical outcomes.",
author = "Murat Ugur and Suri, {Rakesh M.} and Daly, {Richard C.} and Dearani, {Joseph A.} and Park, {Soon J.} and Joyce, {Lyle D.} and Burkhart, {Harold M.} and Greason, {Kevin L.} and Schaff, {Hartzell V}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.jtcvs.2013.12.051",
language = "English (US)",
volume = "148",
pages = "1940--1946",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Comparison of early hemodynamic performance of 3 aortic valve bioprostheses

AU - Ugur, Murat

AU - Suri, Rakesh M.

AU - Daly, Richard C.

AU - Dearani, Joseph A.

AU - Park, Soon J.

AU - Joyce, Lyle D.

AU - Burkhart, Harold M.

AU - Greason, Kevin L.

AU - Schaff, Hartzell V

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Objective The study objective was to determine whether the new-generation Trifecta (St Jude Medical Inc, St Paul, Minn) bovine aortic valve bioprosthesis, which is designed for supra-annular positioning, produces early postoperative hemodynamic results comparable to or better than those of the Mitroflow (Sorin Group, Milan, Italy) or Perimount Magna (Edwards Lifesciences Corp, Irvine, Calif) bovine aortic valve bioprostheses.Methods We retrospectively reviewed the medical records of patients who underwent aortic valve replacement with a Trifecta, Mitroflow, or Perimount Magna bovine pericardial prosthesis at Mayo Clinic between June 2007 and December 2012 and analyzed early postoperative hemodynamic performance by Doppler echocardiography.Results A total of 1436 patients underwent aortic valve replacement (Trifecta in 196, Mitroflow in 1135, Perimount Magna in 105). Preoperative characteristics and early clinical outcomes were similar among the 3 valve groups. The average mean gradients were lower and valve areas were greater with the Trifecta valves. For the Trifecta, Mitroflow, and Perimount Magna valves, the average mean gradient was 11.4 mm Hg, 16.9 mm Hg, and 14.1 mm Hg, respectively; the effective orifice area was 2.22 cm2, 1.85 cm2, and 2.09 cm2, respectively; and the indexed effective orifice area was 1.14 cm2/m2, 0.96 cm2/m2, and 1.07 cm2/m2, respectively (all P <.001). Similar statistical significance was found when data were stratified by valve size. Severe prosthesis-patient mismatch (indexed effective orifice area <0.60 cm2/m2) was detected in 1.3% of patients (n = 2/150) with the Trifecta, 5.8% of patients (n = 44/758) with the Mitroflow, and 3.2% of patients (n = 3/95) with the Perimount Magna (P =.048).Conclusions Early hemodynamic postoperative performance of the Trifecta bioprosthesis is favorable. Additional follow-up should determine whether these small hemodynamic differences will persist and influence later clinical outcomes.

AB - Objective The study objective was to determine whether the new-generation Trifecta (St Jude Medical Inc, St Paul, Minn) bovine aortic valve bioprosthesis, which is designed for supra-annular positioning, produces early postoperative hemodynamic results comparable to or better than those of the Mitroflow (Sorin Group, Milan, Italy) or Perimount Magna (Edwards Lifesciences Corp, Irvine, Calif) bovine aortic valve bioprostheses.Methods We retrospectively reviewed the medical records of patients who underwent aortic valve replacement with a Trifecta, Mitroflow, or Perimount Magna bovine pericardial prosthesis at Mayo Clinic between June 2007 and December 2012 and analyzed early postoperative hemodynamic performance by Doppler echocardiography.Results A total of 1436 patients underwent aortic valve replacement (Trifecta in 196, Mitroflow in 1135, Perimount Magna in 105). Preoperative characteristics and early clinical outcomes were similar among the 3 valve groups. The average mean gradients were lower and valve areas were greater with the Trifecta valves. For the Trifecta, Mitroflow, and Perimount Magna valves, the average mean gradient was 11.4 mm Hg, 16.9 mm Hg, and 14.1 mm Hg, respectively; the effective orifice area was 2.22 cm2, 1.85 cm2, and 2.09 cm2, respectively; and the indexed effective orifice area was 1.14 cm2/m2, 0.96 cm2/m2, and 1.07 cm2/m2, respectively (all P <.001). Similar statistical significance was found when data were stratified by valve size. Severe prosthesis-patient mismatch (indexed effective orifice area <0.60 cm2/m2) was detected in 1.3% of patients (n = 2/150) with the Trifecta, 5.8% of patients (n = 44/758) with the Mitroflow, and 3.2% of patients (n = 3/95) with the Perimount Magna (P =.048).Conclusions Early hemodynamic postoperative performance of the Trifecta bioprosthesis is favorable. Additional follow-up should determine whether these small hemodynamic differences will persist and influence later clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84911008118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911008118&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2013.12.051

DO - 10.1016/j.jtcvs.2013.12.051

M3 - Article

C2 - 24530199

AN - SCOPUS:84911008118

VL - 148

SP - 1940

EP - 1946

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 5

ER -